More Videos
|
CNBC'S MOST SHARED
- 'We're in the Middle of a Crash': Black Swan
- The Rising Mountain of Debt May Be the Next Crisis
- SEC May Reinstate Rules for Short-Selling Stocks
- Latvian Banker Taking Souls as Collateral
- A Goldman Trading Scandal?
- Cuddle Parties Heat Up
- Alaska Governor Sarah Palin Will Resign
- The Worst Expected 2010 State Budget Gaps
- NY City Apartment Sales Down More Than 50%
- Fireworks At Pharma's Market
- Value of Warren Buffett's Annual Gift to Gates Foundation Falls Along With Berkshire's Stock
- Michael Jackson: The Music And The Money
- Five Stock Picks for This Market
- Realities of the New Obama Refis
- Weak Dollar Means Gold at $1,040: Strategist
- Court Ruling Could Mean Trouble for TiVo
- Lance, Please Back Out Of Tour
- TeleMedicine Gets An Apple App Store Facelift
- A Goldman Trading Scandal?
- Top Videos: From the Black Swan to the Bond King
- Obama Plan Would Trim Back Financial Powerhouses
- Biden: 'We Misread How Bad The Economy Was'
- FedEx Sees Signs of a Turnaround: Report
- Property Tax Appeals Take Toll on Governments
- Chrysler Names Remaining Directors to New Board
- Car Dealer Determined To Fight Chrysler Over Franchise
- 'Ice Age' Heats Up Worldwide Box Office
PHARMA'S MARKET VIDEO
RSS FEED
Text Size 
Shares of Amylin are ambling higher today after two destructive trading days.
First, last Friday, Novo Nordisk put out a press release saying preliminary data show its drug works better than Byetta. And then, yesterday an analyst downgraded the stock just ahead of the company's long anticipated release of long-term results on its once-a-week version of Byetta.
So, today the shoe's on the other foot for NVO [NVO
Loading...
()
]. You can hear what AMLN CEO Dan Bradbury thinks of Novo's Friday press release in the video clip below, from his "First on CNBC" interview on "Squawk on the Street" this morning.
The stocks have changed direction after Amylin [AMLN
Loading...
()
], Eli Lilly [LLY
Loading...
()
] and Alkermes [ALKS
Loading...
()
] announced that after one year patients on once-a-week Byetta saw a key measure of their blood sugar level drop two percentage points and their weight go down nearly 10 pounds.
FBR biotech analyst Jim Reddoch calls the results "unprecedented." David Kliff of the "Diabetic Investor" newsletter says, ""Quite frankly the results...aren't great they're astonishing." Rodman & Renshaw's Mike King in a research note to clients writes that they're "incredibly consistent results."
But Swiss drugmaker Roche also announced test results here on a similar once-a-week product. Wachovia analyst George Farmer says Roche's drug, which is moving into late-stage studies, "emerges as a strong competitor."
Combined with Novo's test results on a one-a-day version of the same class of drug Farmer says, "We see credible competition to AMLN's (Byetta) franchise beginning to emerge by 2010."
Wachovia, FBR and R&R make a market in AMLN. FBR would also like to bank the company.
In his wrap-up ADA meeting note to subscribers today Kliff concludes, "In this heavyweight fight Novo threw everything they had at Amylin who was able to withstand the assault. In the end investors should thank the people at Novo for creating a great entry point into Amylin shares. While a bit bloody after a tough few days, Amylin remains the most valuable property in the diabetes space."
Who knew bloody fights could break out at scientific meetings?
 |
Actos Booth To the right of Mike is HDL or "good" cholesterol. To his left in green is a triglyceride. The photo was taken at the booth for the diabetes drug Actos on the exhibit floor at the ADA meeting at Moscone Center in San Francisco. |
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes